Subject category:
Production and Operations Management
Published by:
Vlerick Business School
Length: 17 pages
Data source: Field research
Share a link:
https://casecent.re/p/200812
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
The case describes the trajectory of Pfizer's plant in Puurs, Belgium, towards becoming a lead plant within Pfizer's international network. Additionally, it examines how the plant can maintain this position in the future. Having been the exclusive site outside the United States for producing the COVID-19 vaccine, the key question emerges: how should the plant evolve, and what additional capabilities should it cultivate to continue its leadership role? The case delves into the journey of the Belgian plant, navigating through the aftermath of mergers, acquisitions, and restructuring within Pfizer's global production network from 2000 to 2020. It chronicles the development of crucial capabilities that not only ensured the plant's continued existence, but also how it garnered the trust of senior management to undertake in 2020 the pivotal task of producing the COVID-19 vaccine, which it accomplished with phenomenal success. The case ends with Luc Van Steenwinkel, VP Operations and Site Leader, and his team wondering what the best strategy would be for the plant to sustain its successful trajectory. Should it prioritize increasing its scale or broadening its scope? Or could it do both?
Teaching and learning
This item is suitable for postgraduate and executive education courses.Time period
The events covered by this case took place in 2021-2023.Geographical setting
Region:
Europe
Country:
Belgium
Location:
Puurs
Featured company
Pfizer
Type:
Public company
Industry:
Biopharmaceutical company
Featured protagonist
- Luc Van Steenkiste (male), Vice President Pfizer Biotech Operations and Pfizer Puurs Site Leader
About
Abstract
The case describes the trajectory of Pfizer's plant in Puurs, Belgium, towards becoming a lead plant within Pfizer's international network. Additionally, it examines how the plant can maintain this position in the future. Having been the exclusive site outside the United States for producing the COVID-19 vaccine, the key question emerges: how should the plant evolve, and what additional capabilities should it cultivate to continue its leadership role? The case delves into the journey of the Belgian plant, navigating through the aftermath of mergers, acquisitions, and restructuring within Pfizer's global production network from 2000 to 2020. It chronicles the development of crucial capabilities that not only ensured the plant's continued existence, but also how it garnered the trust of senior management to undertake in 2020 the pivotal task of producing the COVID-19 vaccine, which it accomplished with phenomenal success. The case ends with Luc Van Steenwinkel, VP Operations and Site Leader, and his team wondering what the best strategy would be for the plant to sustain its successful trajectory. Should it prioritize increasing its scale or broadening its scope? Or could it do both?
Teaching and learning
This item is suitable for postgraduate and executive education courses.Settings
Time period
The events covered by this case took place in 2021-2023.Geographical setting
Region:
Europe
Country:
Belgium
Location:
Puurs
Featured company
Pfizer
Type:
Public company
Industry:
Biopharmaceutical company
Featured protagonist
- Luc Van Steenkiste (male), Vice President Pfizer Biotech Operations and Pfizer Puurs Site Leader